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ABSTRACT
The object of this review is to provide 
the definitions, frequency, risk factors, 
pathophysiology, diagnostic considerations, 
and management recommendations for diabetic 
ketoacidosis (DKA) in children and adolescents, 
and to convey current knowledge of the causes 
of permanent disability or mortality from 
complications of DKA or its management, 
particularly the most common complication, 
cerebral edema (CE). DKA frequency at the 
time of diagnosis of pediatric diabetes is 
10%-70%, varying with the availability of 
healthcare and the incidence of type 1 diabetes 
(T1D) in the community. Recurrent DKA rates 
are also dependent on medical services and 
socioeconomic circumstances. Management 
should be in centers with experience and where 
vital signs, neurologic status, and biochemistry 
can be monitored with sufficient frequency to 
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prevent complications or, in the case of CE, to 
intervene rapidly with mannitol or hypertonic 
saline infusion. Fluid infusion should precede 
insulin administration (0.1 U/kg/h) by 1-2 hours; 
an initial bolus of 10-20 mL/kg 0.9% saline is 
followed by 0.45% saline calculated to supply 
maintenance and replace 5%-10% dehydration. 
Potassium (K) must be replaced early and 
sufficiently. Bicarbonate administration is 
contraindicated. The prevention of DKA at onset 
of diabetes requires an informed community and 
high index of suspicion; prevention of recurrent 
DKA, which is almost always due to insulin 
omission, necessitates a committed team effort.
Keywords: adolescents; cerebral edema; 
children; complications; diabetic ketoacidosis; 
fluid replacement; hypokalemia; management; 
prevention; recurrent DKA
INTRODUCTION
Definition of Diabetic Ketoacidosis
Diabetic ketoacidosis (DKA) is biochemically 
defined as a venous pH <7.3 or serum 
bicarbonate concentration <15 mmol/L, serum 
glucose concentration >200 mg/dL (11 mmol/L) 104 Diabetes Ther (2010)  1(2):103-120.
together with ketonemia, glucosuria, and 
ketonuria.1,2 Rarely, DKA may occur with normal 
circulating glucose concentrations if there has 
been partial treatment or with pregnancy.3,4 The 
severity of DKA is determined by the degree 
of acidosis:2
Mild: venous pH >7.2 and <7.3, bicarbonate  •	
<15 mmol/L
Moderate: venous pH >7.1 and <7.2,  •	
bicarbonate <10 mmol/L
Severe: venous pH <7.1, bicarbonate  •	
<5 mmol/L.
Pathophysiology
DKA is the result of a critical relative or 
absolute deficit of insulin, resulting in 
intracellular starvation of insulin-dependent 
tissues (muscle, liver, adipose), stimulating 
the release of the counter-regulatory 
hormones glucagon, catecholamines, cortisol, 
and growth hormone. The counter-regulatory 
hormonal responses may also be the result of 
stress-induced proinflammatory cytokines.5
They stimulate lipolysis and proteolysis, 
Figure 1. Pathophysiology of diabetic ketoacidosis. Absolute or relative insulin deficiency decreases glucose utilization in 
insulin-sensitive tissues and promotes lipolysis. Energy deficiency in these tissues is a stress, stimulating counter-regulatory 
hormones (glucagon, catecholamines, growth hormone, cortisol) and proinflammatory cytokines, which also stimulate these 
hormones. The counter-regulatory hormones in turn enhance lipolysis and proteolysis, providing a substrate for hepatic 
ketogenesis and hepatic and renal gluconeogenesis, all of which results in ketoacidosis, osmotic diuresis, dehydration, and 
tissue hypoperfusion, adding lactic acidosis to the metabolic acidosis from accumulated ketones and loss of base in the urine.
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hepatic and renal glucose production, and 
hepatic oxidation of fatty acid to ketone 
bodies.6 Unlike during physiologic fasting, 
absence of citric acid cycle processing of 
glucose impedes the processing of these 
ketones for energy (Figure 1).
Frequency and Risk Factors
DKA with New-Onset Diabetes
The frequency of new-onset diabetes presenting 
as DKA varies widely by geographic region, and 
correlates inversely with the regional incidence, 
and therefore the level of awareness in the 
community of pediatric diabetes. In Europe 
this frequency varies from 11% to 67%.7 In 
Australia the frequency between 1985 and 2000 
was 26%,8 and in New Zealand 63% in 1988/89 
and 42% in 1995/96.9 Children <5 years of 
age are more likely to have DKA at diagnosis 
as are those who are in social or economic 
situations that do not permit ready access to 
medical care.2,7-14 In patients from Colorado, 
DKA was seen at onset in 28.4%; the odds ratio 
for uninsured patients compared with insured 
patients was 6.2, with significantly greater 
severity in the uninsured group.12 Long-term 
reductions in frequency of DKA at onset have 
been reported following intensive education of 
the medical and lay community.8-10 DKA at the 
time of diagnosis has been estimated to occur 
in as many as 25% of children with type 2 
diabetes (T2D).2
It is not uncommon for previously 
undiagnosed patients in DKA to have been 
seen in physicians’ offices or emergency rooms 
without adequate history and laboratory study 
that could have made the diagnosis before 
they became critically ill. A high index of 
suspicion is particularly warranted for infants 
and young children whose symptoms may 
be nonspecific.
Recurrent DKA
Among 1243 patients in Colorado, the risk of 
recurrent DKA was eight episodes per 100 patient 
years; 20% of the patients accounted for 80% 
of the episodes. The risk factors for recurrent 
DKA were poor metabolic control or previous 
episodes of DKA, female gender (peripubertal 
or adolescent), psychiatric disorders including 
eating disorders, difficult or unstable family 
circumstances, limited access to medical 
services, and insulin pump therapy.12 Only 
rapid- or short-acting insulin is used in pumps, 
so that interruption of insulin delivery for 
any reason rapidly leads to insulin deficiency. 
In the 1970s and 1980s, the establishment 
of treatment teams with intensive education 
of families on sick day management and 
24-hour availability demonstrated a profound 
reduction in recurrent DKA, which is almost 
invariably due to intentional omission of 
insulin administration.15,16
Diagnosis and Initial Evaluation
Hyperglycemic hyperosmolar state (HHS) defined 
as serum glucose >600 mg/mL (33 mmol/L), 
serum osmolality >320 mOsm/L, and minimal 
ketonemia/ketonuria, is being seen with 
increasing frequency as the presenting indication 
of T2D and may be associated with mild-to-
moderate acidosis from severe dehydration, 
leading to confusion with DKA.17 Conversely, 
patients with type 1 diabetes (T1D) may have 
features of HHS, especially if they have been 
satisfying their polydipsia with fluids containing 
a high concentration of glucose.18 HHS has a 
substantial mortality rate and requires aggressive 
reconstitution of the circulatory volume.17-20
Body weight should be determined for 
calculation purposes. Dehydration can be 
estimated as 5% if there is reduced skin elasticity, 
dry mucous membranes, tachycardia, and 106 Diabetes Ther (2010)  1(2):103-120.
deep breathing, and up to 10% with capillary 
refill time greater than 3 seconds and sunken 
eyes (Table 1). Calculations of fluid deficit are 
commonly based on 10% dehydration, which 
in most cases is a modest overestimate that does 
not appear to have clinical significance.21-22 
The level of consciousness should be recorded 
using the Glasgow Coma Scale (Table  2).23 
An initial venous blood sample should be 
tested for glucose; electrolytes; pH; urea 
nitrogen; creatinine; osmolality; ketones 
or beta-hydroxybutyrate; hemoglobin and 
hematocrit or complete blood count, while 
keeping in mind that DKA is associated   
with leukocytosis.
Osmolality can be measured or calculated 
as: 2× (sodium [Na] + K) + glucose in millimoles 
per liter (or glucose in mg/dL/18). The urine 
should be checked for ketones. If there is any 
possibility of delay in obtaining a serum K result, 
Table 1. Estimating the level of dehydration.
Mild 
(infants ≤5%/ 
children ≤3 %)
Moderate 
(infants 6%-10%/ 
children 4%-6%)
Severe 
(infants >10%-15%/ 
children >6%-10%)
Clinical state Alert Drowsy, irritable Lethargic/obtunded
Blood pressure Normal Normal Low
Heart rate Normal Increased/weak pulse Rapid/feeble pulse
Capillary refill Normal =2 seconds >3 seconds
Skin turgor Normal Tenting* Absent*
Eyes Normal Slightly sunken/reduced eyeball turgor Sunken/soft eyeballs
Oral mucosa/lips Moist Dry Very dry/parched
Urine output Normal Reduced  Anuric
*Note that with severe hyperosmolality, skin and subcutaneous tissue are doughy rather than hypeoelastic.
Table 2. Glasgow Coma Scale (GCS). Reprinted with permission.2
Best eye response  Best verbal response
Best verbal response  
(nonverbal children) Best motor response
1. No eye opening
2. Eyes open to pain
3. Eyes open to verbal  
  command
4. Eyes open spontaneously
1. No verbal response
2. No words, only  
  incomprehensible sounds;  
  moaning and groaning
3. Words, but incoherent*
4. Confused, disoriented  
  conversation†
5. Orientated, normal  
  conversation
1. No response
2. Inconsolable, irritable,  
  restless, cries
3. Inconsistently consolable and  
  moans; makes vocal sounds
4. Consolable when crying and  
  interacts inappropriately
5. Smiles, oriented to sound,  
  follows objects and interacts
1. No motor response
2. Extension to pain  
  (decerebrate posture)
3. Flexion to pain  
  (decorticate posture)
4. Withdrawal from pain
5. Localizes pain
6. Obeys commands
The GCS consists of three parameters and is scored between 3 and 15; 3 being the worst and 15 the best. One of the 
components of the GCS is the best verbal response, which cannot be assessed in nonverbal young children. A modification of 
the GCS was created for children too young to talk.
*Inappropriate words, no sustained conversational exchange.
†Attention can be held; responds in a conversational manner, but shows some disorientation.Diabetes Ther (2010)  1(2):103-120. 107
electrocardiographic monitoring should be done 
for K status.24,25 Severely ill patients should have 
continuous electrocardiographic monitoring 
using standard lead II or if the initial K level is 
≤3 mEq/L or ≥6 mEq/L (Figure 2).26
Glycohemoglobin (HbA1c) concentration 
will provide information about the severity and 
duration of hyperglycemia in newly diagnosed 
patients and can be compared with the previous 
determination as an indicator of noncompliance 
leading to the DKA in an established patient. 
Measurement of serum-free insulin concentration 
before the administration of insulin can confirm 
an impression of failure to administer insulin as 
the cause of recurrent DKA.27
The severely obtunded child will require 
continuous nasogastric suction for the 
prevention of pulmonary aspiration and may 
require oxygen. Bladder catheterization should 
be performed only in individuals who are unable 
to void on demand; older patients may have an 
atonic bladder with urinary retention requiring 
initial catheterization, but not indwelling.28
MANAGEMENT
Children with established diabetes, who are not 
vomiting or severely ill, and whose caregiver 
has been trained in sick day management, 
can be managed at home or at an outpatient 
facility, with appropriate supervision and 
follow-up.2,29-32 Children who are vomiting 
and not severely ill may be managed with 
intravenous (IV) fluids in an emergency 
department and discharged to home if able 
to take fluids orally following rehydration, 
if venous pH is above 7.25, and telephone 
follow-up can be assured. Children requiring IV 
rehydration over an extended period need to be 
admitted to a unit in which neurological status 
and vital signs can be monitored frequently and 
blood glucose levels measured hourly.2 Nursing 
staff trained in monitoring and management of 
DKA should be available and written guidelines 
should be provided.2,32 With severe DKA 
(long duration of symptoms, compromised 
circulation, depressed level of consciousness) 
Figure 2. Electrocardiographic patterns for hypo- and hyperkalemia.
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or if there are other factors increasing the risk 
for cerebral edema (CE; age under 5 years, low 
partial pressure of carbon dioxide [pCO2], high 
serum urea nitrogen), an intensive care unit, 
preferably pediatric, or an equivalent facility 
is appropriate.2
Fluid and Insulin Replacement
Goals of Treatment with Fluid and Insulin
Restore perfusion, which will increase  •	
glucose uptake in the periphery, increase 
glomerular filtration, and reverse the 
progressive acidosis.
Arrest ketogenesis with insulin  •	
administration, which reverses proteolysis 
and lipolysis while stimulating glucose 
uptake and processing, thereby normalizing 
blood glucose concentration.
Replace electrolyte losses. •	
Intervene rapidly when complications,  •	
especially CE, occur.
Fluid Therapy
Dehydration can be assumed to be 5%-10%  •	
(50-100 mL/kg). As noted above, the degree 
of dehydration is usually overestimated. 
The severity of extracellular fluid (ECF) 
contraction may be indicated by serum urea 
and hematocrit concentrations.11 Serum Na 
concentration is not reliable for determining 
ECF deficit because of the osmotic effect 
of hyperglycemia-induced dilutional 
hyponatremia33,34 and the low Na content 
of the elevated lipid fraction of the serum 
in DKA. Corrected Na, ie for normal glucose 
levels, can be estimated by adding 1.6 mEq 
to the measured value for each 100 mg/dL 
blood glucose above normal.33
During the first 1-2 hours, 10-20 mL/kg 0.9%  •	
sodium chloride (NaCl) should be provided 
to restore peripheral perfusion.
Maintenance can be calculated as 1000 mL  •	
for the first 10 kg body weight + 500 mL for 
the next 10 kg + 20 mL/kg over 20 kg or 
1500 mL/m2 body surface area.
The remainder of replacement after the  •	
loading dose, based on 5%-10% dehydration, 
and maintenance, can be distributed over 
the subsequent 22-23 hours. While many 
guidelines call for calculating replacement 
over 48 hours, there is no evidence basis for 
this being safer or more efficacious. Fluids 
that have recently been administered orally 
at home (if not vomited) and parenteral 
fluids provided in the emergency room or 
referring institution need to be incorporated 
into the calculation.
Except for severely ill and very young  •	
individuals, oral intake should begin before 
24 hours.
While urinary output should be carefully  •	
documented, urinary losses should not be 
added to fluid requirements, except in the 
presence of HHS.2,17,20
After initial 0.9% NaCl bolus, rehydration/ •	
maintenance should be continued with 
0.45% NaCl. The measured Na can increase 
to the level of the corrected Na during 
rehydration as glycemia declines and then 
decline to normal levels if the corrected 
level was elevated.
Continued use of 0.9% saline after the initial  •	
resuscitation may result in hyperchloremic 
metabolic acidosis.35,36
To prevent unduly rapid decline in plasma  •	
glucose concentration and hypoglycemia, 
5% glucose should be added to the IV fluid 
when the plasma glucose falls to 300 mg/dL 
(17 mmol/L). An efficient method of 
providing glucose as needed without 
long delays entailed by the changing 
of IV solutions is to have two IV fluid 
bags connected, one containing 10% Diabetes Ther (2010)  1(2):103-120. 109
dextrose and the appropriate Na and K 
concentrations and the other with the same 
salt concentrations but no dextrose, the 
so-called “two bag system”.37
K (40 mEq/L or up to 80 mEq/L as needed)  •	
can be provided as half potassium chloride 
(KCl), half potassium phosphate (KPO4; 
to replenish low phosphate levels and to 
decrease the risk of hyperchloremia) or 
as half KPO4 and half K acetate (which, 
like lactate, is converted to bicarbonate 
to help correct acidosis) after serum K is 
<6 mmol/L or urine flow is established. 
Serum K concentration increases by 
approximately 0.6 mEq/L for every 
0.1 decrease in pH, so that the serum 
K level does not reflect the large deficit 
from diuresis and vomiting, ~5 mEq/kg 
body weight. Both K and phosphate shift 
markedly from intracellular to extracellular 
compartments with acidosis and re-enter 
cells rapidly with insulin-induced glucose 
uptake and rehydration.26,38
Bicarbonate administration is not  •	
indicated in pediatric DKA. There is no 
evidence that bicarbonate facilitates 
metabolic recovery. Restoring circulatory 
volume will improve tissue perfusion 
and renal function, increasing organic 
acid excretion and reversing lactic 
acidosis. The administration of insulin 
stops further synthesis of ketoacids and 
reactivates the Krebs cycle, permitting 
metabolism of ketoacids, and regeneration 
of bicarbonate. Bicarbonate therapy 
may cause paradoxical central nervous 
system (CNS) acidosis, rapid correction 
of acidosis can cause hypokalemia, the 
additional Na can add to hyperosmolality, 
and alkali therapy can increase 
hepatic ketone production, potentially 
slowing recovery.2
Insulin
Insulin should be started after initial fluid  •	
expansion. This provides a more realistic 
starting glucose level.
0.1 U/kg/hour is given as a continuous  •	
infusion, using a pump. Fifty units of regular 
insulin are diluted in 50 mL normal saline 
to provide 1 unit/mL.
A bolus dose of insulin is not indicated and  •	
may increase the risk of CE.39
In some settings it may be necessary to  •	
administer insulin subcutaneously. Studies 
in adults have indicated no significant 
difference in recovery time whether 
insulin was administered intravenously, 
intramuscularly, or subcutaneously after 
the first couple of hours of treatment.40,43
A study of subcutaneous insulin in 
children with DKA using a rapid-acting 
insulin analog (lispro) provided a dose of 
0.15 units/kg every 2 hours; there were 
no significant differences from children 
randomized to receive 0.1 unit/kg per 
hour intravenously.44 The administration 
of 0.1 unit/kg subcutaneously every hour 
may be preferable and can be adjusted to 
maintain blood glucose concentrations at 
~180-200 mg/dL (10-11 mmol/L).
Fluid expansion alone will have a dilutional  •	
effect, lowering high blood glucose levels by 
as much as 180-270 mg/dL (10-15 mmol/L). 
With insulin infusion the rate of 
glucose decline should be 50-150 mg/dL 
(2.8-8.3 mmol/L/hour), but not >200 mg/dL 
(11 mmol/L/hour). If serum glucose 
values are not dropping adequately, the 
insulin dose should be increased; this is 
rarely necessary.
If the blood glucose concentration falls  •	
below 150 mg/dL (8.3 mmol/L) 10% 
dextrose solution should be given and the 
insulin dose reduced to 0.05 U/kg/hour if 110 Diabetes Ther (2010)  1(2):103-120.
glucose concentration is not sustained by 
the 10% dextrose solution.
Insulin should not be stopped; a continuous  •	
supply of insulin is needed to prevent 
ketosis and permit continued anabolism. If 
the patient demonstrates marked sensitivity 
to insulin, the dose may be decreased to 
0.05 units/kg/hour, or less, provided that 
metabolic acidosis continues to resolve.
Persistent acidosis, defined as bicarbonate  •	
value <10  mmol/L after 8-10  hours of 
treatment, is usually caused by inadequate 
insulin effect. Insulin dilution and rate of 
administration should be checked, and 
a fresh preparation made. Too dilute a 
solution may enhance insulin adherence 
to the tubing. If insulin is being given 
by subcutaneous injection, inadequate 
absorption may be occurring. Rare causes 
of persistent acidosis include lactic 
acidosis due to an episode of hypotension 
or apnea or inadequate renal handling of 
hydrogen ion as a result of an episode of 
renal hypoperfusion.28
Monitoring
Successful management and early intervention 
for complications requires close monitoring. A 
flow chart should be maintained to document 
all relevant incidents regarding the patient’s 
condition.28 Minimal monitoring frequency 
recommendations include vital signs and 
neurologic checks hourly; blood glucose 
hourly; venous blood gases every 2 hours for 
6 hours, then every 4 hours; Na, K, and ionized 
calcium every 2 hours for 6 hours, then every 
4 hours; magnesium and phosphorus every 
4 hours; basic metabolic profile at admission 
and then every morning. These minimum 
requirements should be adapted to the 
situation; for example, more frequent (hourly) 
K measurements may be indicated, along 
with electrocardiogram (ECG) monitoring 
depending on the initial K value,24,25 or more 
frequent neurologic and vital sign checks 
(20-30 minutes) if there is a concern about the 
patient’s mental status.28
Ketonuria should not be used as a measure 
of improvement. The dip sticks used to measure 
ketones react with acetoacetate. Concentrations 
of beta-hydroxybutyrate are much higher than 
those of acetoacetate and will be converted to 
acetoacetate during successful treatment of 
the DKA, resulting in sustenance or increase 
of urinary ketone concentration. Laboratory 
measurement or the use of a bedside fingerstick 
sample monitor for beta-hydroxybutyrate will 
avoid this problem.
Transition
IV fluids can be stopped 1-2 hours after  •	
substantial consumption of oral fluids 
without vomiting.
Subcutaneous insulin injection can be  •	
started when IV fluids are no longer 
needed. Presupper or prebreakfast time is 
most convenient for starting or restarting 
intermediate- or long-acting insulin. Before 
then, rapid-acting or regular insulin 0.25 U/kg   
subcutaneously can be given every 
~6 hours, and the insulin infusion stopped 
60-120 minutes after the first subcutaneous 
dose of regular insulin or 60 minutes after a 
rapid-acting insulin analog.
Patients should not be kept in the hospital  •	
simply to adjust insulin dosage because food, 
activity, and psychosocial environment are 
not normal in the hospital setting. Therefore, 
insulin requirements will not be particularly 
informative for home management.
Established patients with DKA can resume  •	
their usual home dose of insulin.Diabetes Ther (2010)  1(2):103-120. 111
COMPLICATIONS OF DKA OR ITS 
TREATMENT
Most of the diabetes-related morbidity and 
mortality in childhood T1D can be attributed 
to complications of DKA.2 Mortality risks 
for each episode of DKA have been reported 
from the United States (0.15%),45 Canada 
(0.18%-0.25%),46,47 and the United Kingdom 
(0.31%).48 CE accounts for 60%-100% of 
this mortality.45,50 Other causes of death or 
disability with DKA include hypokalemia, 
hypophosphatemia, hypoglycemia, other 
intracerebral complications, peripheral venous 
thrombosis, mucormycosis, rhabdomyolysis, 
acute pancreatitis, acute renal failure, 
sepsis, aspiration pneumonia, and other 
pulmonary complications.2 Prevention of 
hypokalemia was noted in the section of 
fluid therapy. Hypophosphatemia can cause 
progressive muscle weakness and death due to 
cardiorespiratory arrest days after metabolic 
recovery from DKA and can be prevented 
by administration of half of the K as KPO4; 
administration of all the K as KPO4 can result 
in hypocalcemia.51,52
Renal Failure
Renal failure is a common complication and 
cause of mortality with HHS, necessitating early 
consideration of dialysis,17 but is extremely rare 
with pediatric T1D.
Peripheral Venous Thrombosis
Central venous catheter (CVC) placement was 
associated with deep venous thrombosis (DVT) 
in four of eight children with DKA,53 and in 
three of six pediatric intensive care unit (PICU) 
patients with DKA who required femoral CVC 
(out of 113 DKA/PICU patients).54 The PICU 
patients were under 18 months of age and 
required long-term heparin therapy for persistent 
leg swelling; in contrast, seven comparably aged 
patients with shock who had femoral CVC for 
longer periods of time than the DKA patients 
had no episodes of DVT. This suggested that DKA 
is associated with a thrombotic diathesis beyond 
that which is attributable to dehydration. 
In the absence of DKA, coagulation factor 
abnormalities have not been demonstrated in 
children with diabetes,55 but von Willebrand 
factor activity remains elevated at 120 hours 
following admission for DKA.56 Thus, DKA and 
its treatment may promote a prothrombotic 
state and activation of vascular endothelium, 
predisposing to thrombosis.
More than 50% of children who have venous 
thromboses will carry a genetic thrombophilic 
defect, and two-thirds of such defects will be a 
mutation in the factor V gene referred to as factor 
V Leiden.57 Massive arterial thrombosis resulting 
in unilateral below-the-knee amputation has 
been reported in a 12-year-old female patient 
with a heterozygous factor V Leiden mutation 
and a 2-year history of poorly controlled T1D 
who was not in DKA.58
Pancreatitis
Acute pancreatitis is a recognized complication of 
DKA in adults and in new-onset T2D with HHS17 
but is unusual in childhood T1D. Serum levels 
of amylase and lipase were commonly elevated 
in 50 children with DKA at onset of T1D.59 
The amylase elevation is of salivary origin. The 
serum lipase level was directly associated with 
the degree of acidosis, and acute pancreatitis 
was demonstrated by abdominal computed 
tomography (CT) in one of the patients who had 
persistent abdominal pain.59 Acute pancreatitis 
must be considered with abdominal pain that 
does not resolve with correction of acidosis.112 Diabetes Ther (2010)  1(2):103-120.
Rhabdomyolysis
Rhabdomyolysis is a common complication of 
HHS and is associated with renal failure.17 It 
occurs with DKA, but in the absence of HHS is 
not associated with mortality. Risk factors include 
severe hyperglycemia, high osmolality, and 
hypophosphatemia. A 15-month-old was added 
to the few reported pediatric cases in 2003.60 The 
occurrence of rhabdomyolysis in a 27-month-old 
patient 25 years earlier led to a chart review of 
133 children admitted with new-onset diabetes, 
of whom 12 had orthotolidine reactions, which 
detect myoglobin in the urine.61
Mucormycosis
This acute, rapidly progressing, and often fatal 
facultative fungal infection occurs in young 
patients with diabetes who have chronically 
poor glycemic control and ketoacidosis. The 
principal locus may be rhinocerebral, pulmonary, 
cutaneous, gastrointestinal, or in the CNS, 
or it may be disseminated. In a series of five 
patients, the sole survivor had severe neurologic 
disability; risk factors were African American 
race and history of poor compliance (poor clinic 
attendance, risk-taking behaviors, and high rate 
of hospital admission).62
Cerebral Edema
In 1967, two teenage patients were reported 
with fatal CE and only three others were 
identified from the literature with a similar 
clinical history.63 In the subsequent 13 years, 
only 13 more cases were reported.64 In the next 
10 years the total reported cases reached 40 and 
in 1990 an additional 29 were added in one report 
and 11 in another.49,65 Subsequently, another 
~160 cases have been added. These reports have 
provided incidence data and have emphasized 
the idiosyncratic nature of the occurrence of CE 
and the absence of iatrogenic causation.66,67
Frequency
A 3-year United Kingdom population-based 
study yielded an incidence of 0.7% overall, 
with a marked discrepancy between the newly 
diagnosed, 1.2%, and established patients, 
0.4%.68 A higher incidence of 4.3% in newly 
diagnosed, 1.3% in established patients, and 
2% overall was reported from Australia.8 The 
North American multicenter study reported an 
incidence of 0.9% for CE without differences 
between new-onset and established patients.50
In a prospective surveillance study in Canada of 
patients <16 years of age with DKA, there were 
13 verified cases of CE, for a rate of 0.51% of 
episodes of DKA.47 Variations in case definition 
and referral patterns likely explain some of these 
differences in the reported frequencies of CE.
Morbidity and Mortality
Earlier reports may reflect biased fatality and 
residual morbidity data and later recognition 
than more recent population-based observations. 
Appropriate intervention was also less frequent 
in these earlier-reported and litigated cases. 
The first extensive series, in 1990, analyzed 
69 cases, including 40 that were previously 
published, and found a case fatality rate of 64% 
overall. Survival without disability was noted 
in 14%, with disability that did not preclude 
independence in 9%, and severe disability or 
vegetative state in 13%. Among those who were 
treated before respiratory arrest, even if this was 
at the gasping stage, case fatality was only 30%, 
with 30% surviving without disability, 26% with 
disability not precluding independence, and 
13% with severe disability or vegetative state.49
Although the intervention in these cases was 
often inadequate and after severe neurologic 
compromise, the outcome with treatment is Diabetes Ther (2010)  1(2):103-120. 113
similar to those in contemporary population-
based studies. There have been a few case reports 
of CE developing before initiation of treatment 
of DKA and a report from Canada indicated that 
19% of cases of CE were present before treatment 
was undertaken.47,49,50,68
Risk Factors
Young children, especially <5 years of age, are 
at increased risk for the development of CE. 
This may reflect the more rapid deterioration 
in this age group and greater delay in diagnosis 
because of nonspecificity of symptoms. The 
younger brain might also be more susceptible to 
metabolic and vascular changes associated with 
DKA. Severity of acidosis, degree of hypocapnia, 
and elevated serum urea nitrogen, indicators of 
severity of ketoacidosis and dehydration, have 
been noted to be risk factors.2 Although Na 
bicarbonate administration was significantly 
associated with the development of CE in 
one population-based case-control study,50
this association may simply reflect the greater 
severity of ketoacidosis that was not adequately 
controlled for in the case-control design, rather 
than an effect of the bicarbonate.69
CE associated with DKA is rarely seen 
beyond the pediatric age group (0-21 years)67
or in adult patients with HHS, despite rapid 
rehydration and restoration of normal 
glycemia.70 In several studies increased risk of 
CE has been associated with a failure of serum 
Na concentration to increase appropriately 
during treatment for DKA. This may be because 
those who are in the early, presymptomatic 
stages of CE experience changes in the brain 
that result in dysregulation of antidiuretic 
hormone secretion.50,71 The absence of evidence 
of associations between volume or tonicity of 
fluids or the rate of change in serum glucose 
and risk of CE indicates that this might be 
the result of altered renal Na handling due to 
cerebral injury, rather than the type or rate of 
fluid administration.2,47,49,65,71
In the 61 children with CE from a 
North American multicenter study, worse 
outcomes occurred in those with greater 
neurologic depression at the time of diagnosis 
of CE and with higher initial serum urea 
nitrogen concentrations.50,72 Intubation and 
hyperventilation to a pCO2 of <22 mmHg also was 
associated with worse outcome, dictating the need 
for caution in hyperventilating patients.2,72
Mechanisms
CE refers to an increase of cerebral tissue water 
causing an increase of tissue volume.73 The 
edema may be vasogenic, due to breakdown of 
the blood-brain barrier, such as around a tumor 
or with trauma; cytotoxic, from poisoning or 
metabolic derangement; or osmotic, as occurs 
with hyponatremia. Neither the cause nor the 
location of the fluid in the swollen brains of 
children with DKA is known. The mechanism 
is likely to be complex, and it may not be the 
same in all affected individuals, as reflected 
by the time of onset and the brain imaging 
findings. The time of onset is distributed in a 
bimodal fashion, with approximately two-thirds 
of patients developing signs and symptoms in 
the first 6-7 hours and the rest from 10-24 hours 
after the start of treatment, with the early-onset 
individuals tending to be younger.50,71,72
Initial brain CT undertaken 2-44 hours after 
the diagnosis of CE found 39% with no acute 
abnormalities visible, and this did not differ 
significantly between early and late-onset 
subjects. Twenty-six percent had diffuse edema, 
which was also similar between early and late 
onset. Three of the eight with diffuse edema 
also had hemorrhages, and 17% of the entire 
group had only subarachnoid or intraventricular 
hemorrhage. Five subjects had focal brain injury 
in the mesial basal ganglia and thalamus, the 114 Diabetes Ther (2010)  1(2):103-120.
periaqueductal gray matter, and the dorsal 
pontine nuclei (22%). These localized injuries 
were only in the early-onset patients. They were 
not an artifact of the time that the studies were 
performed, and thus, truly reflect what appear to 
be widely varying pathology in the brain leading 
to the syndrome that is referred to as “idiopathic 
CE”.71 The observation that approximately 
40% of initial brain imaging studies in 
children who have CE are normal emphasizes 
that CE is a clinical diagnosis requiring the 
initiation of treatment before imaging studies 
are undertaken.
Monitoring
Because treatment modification has not 
prevented CE and with the strong evidence that 
early administration of mannitol prevents brain 
damage and death from this complication, Muir 
et al. developed a model for early detection.71
Diagnostic criteria were abnormal motor or 
verbal response to pain; decorticate or decerebrate 
posture; cranial nerve palsy (especially III, 
IV, VI); and abnormal neurogenic respiratory 
pattern (eg, grunting, tachypnea, Cheyne-
Stokes, apneustic). Major criteria were altered 
mentation/fluctuating level of consciousness; 
sustained heart rate deceleration (decline more 
than 20 per minute) not attributable to improved 
intravascular volume or sleep state; and age-
inappropriate incontinence. Minor criteria 
were vomiting following initial treatment and 
its cessation, if present at admission; headache 
(recurrent and more severe than on admission); 
lethargy or not easily aroused from sleep; diastolic 
blood pressure greater than 90 mmHg; and age 
<5 years. The system allowed 92% sensitivity and 
96% specificity for the recognition of CE early 
enough for intervention, using one diagnostic 
criterion, two major criteria, or one major plus two 
minor criteria. This means that five youngsters 
will be treated for CE to prevent brain damage 
or death in one patient, a reasonable proposition 
considering the alternative of waiting for more 
stringent criteria to be met.
Treatment
Improvement has been consistently observed 
with administration of IV mannitol in a dosage 
of 1.0 g/kg over 20 minutes with repeat as 
necessary in 1-2 hours and associated measures 
as soon as CE is suspected, especially before 
respiratory arrest.2,49,50,65 Intervention includes 
reduction in the rate of fluid administration 
and elevation of the head of the bed. Although 
early intervention with mannitol treatment has 
improved outcome, it is difficult to determine 
to what degree, because increased recognition 
of the problem has undoubtedly led to less 
stringent case definition. The application of 
criteria developed by Muir et al., when applied 
to a series of 69 consecutive cases thought to be 
uncomplicated and experiencing full recovery, 
yielded three (4.3%) who would have been 
appropriately treated with mannitol according 
to these criteria.71 This is remarkably close to the 
percentage of DKA patients treated as CE in a 
recent report of 18 years experience.76
Mannitol lowers the hematocrit and blood 
viscosity, improving cerebral blood flow (CBF) 
and oxygenation, red cell deformability, and 
vasoconstriction in areas of the brain with 
intact autoregulation. It may also improve 
autoregulation from the effects on CBF and 
oxygenation, and has direct osmotic effects with 
reduction in extracellular free water. Intensivists 
frequently express concern about the use of 
mannitol because of their experience with the 
risk of rebound edema and renal failure when 
mannitol is used over an extended period. 
However, there are no reports of complications 
of mannitol use in this acute situation.
Hypertonic saline (HS) has become the standard 
for treating acute intracranial hypertension in Diabetes Ther (2010)  1(2):103-120. 115
head injury and following surgical procedures 
in the supratentorial region and in these 
circumstances has been considered at least as 
effective as mannitol.75-79 HS for treatment of CE 
in DKA was initially described in a 13-year-old 
female patient who developed a severe headache 
20 minutes after the start of treatment and who 
had CT evidence of diffuse CE with transtentorial 
herniation. She continued to deteriorate despite 
mannitol treatment and was given 5 mL/kg of 
3% saline rapidly; she awoke with recovered 
neurologic function within 5 minutes.80 The use 
of 5-10 mL/kg 3% saline in patients who have not 
responded adequately to mannitol infusion of a 
dose of 1 g/kg appears justified.
Intubation should be reserved for those 
with respiratory compromise, but should not 
be undertaken simply because of the diagnosis 
of CE. Aggressive hyperventilation was a 
significant risk factor for poor outcome in the 
study of Marcin et al.,72 similar to detrimental 
effects reported in head trauma and high-
altitude exposure.81,82
Intracerebral Complications other than CE
Approximately 10% of all instances of 
neurologic collapse during ketoacidosis can 
be attributed to intracerebral complications, 
with or without associated edema, but by 
definition not idiopathic CE.2 The causes include 
subarachnoid hemorrhage,49 basilar artery 
thrombosis,49 cerebral venous thrombosis,83,85
meningoencephalitis,86 and disseminated 
intravascular coagulation.87,88
PREVENTION OF DKA
Prevention of DKA at onset is most dramatically 
demonstrated when early diagnosis is made 
through genetic and immunologic screening of 
high-risk children.7,15 For the general population, 
an example has been provided by the Italian 
School and Physician Awareness Program 
directed at 6-14-year-olds, which reduced the 
rates of new-onset DKA from 78% to nearly 0% 
over 6 years10 Materials used in this effort are 
available online.89
In the 1970s, a comprehensive approach 
involving outreach clinics, frequent routine and 
emergency telephone contact, and a camping 
program supported by state funding for children 
with special healthcare needs dramatically 
reduced recurrent DKA episodes. Private 
patients in the program had a reduction in 
hospital admission days from preintervention of 
2.8/patient/year to 0.3 and in the second 
year to 0. The children sponsored by the state 
program had a reduction from 4.9/patient/year 
to 1.8 and in the second year to 0.9.15
Patients with compliance problems account 
for a disproportionate number of recurrent 
DKA episodes. In the UK surveillance study, 
4.8% of patients accounted for 22.5% of all 
episodes68 and as noted above, 20% of patients 
in Colorado accounted for 80% of recurrent DKA 
episodes.14 The principal immediate reason for 
the recurrent DKA in children and adolescents 
is insulin omission, reflected in low or absent 
levels of free insulin.27 The necessity for assuring 
administration of insulin by responsible adults 
is critical.
CONCLUSION
DKA is the result of absolute or relative 
deficiency of insulin in combination with 
exuberant secretion of counter-regulatory 
hormones (glucagon, catecholamines, cortisol, 
growth hormone) resulting in blockade of 
glucose utilization in insulin-sensitive tissues 
(liver, fat, muscle) and a cascade of derangement 
progressing to ketoacidosis and dehydration. 
Much new-onset DKA can be prevented by 116 Diabetes Ther (2010)  1(2):103-120.
increased awareness of early signs and symptoms 
of diabetes and, in principle, almost all 
recurrent DKA is preventable by informed sick 
day management, recognition of psychosocial 
problems leading to insulin omission, and 
careful monitoring of insulin pump function.
Management of DKA should occur in centers 
with treatment experience and monitoring 
capability. Fluid replacement begins with 0.9% 
saline to restore circulation and subsequent 
0.45% saline for maintenance and replacement 
of 5%-10% dehydration, according to severity 
indicators. Whether levels of serum K are normal 
or elevated, there will be a total K deficit that must 
be dealt with early and sufficiently. Bicarbonate 
administration is neither necessary nor safe. 
Mannitol or hypertonic saline should be at the 
bedside, for rapid intervention as indicated for 
CE, the most common serious complication of 
DKA. Other complications include hypokalemia, 
hypophosphatemia, hypoglycemia, intracerebral 
complications other than CE, peripheral 
venous thrombosis, mucormycosis, aspiration 
pneumonia, rhabdomyolysis, acute pancreatitis, 
and acute renal failure. Among questions that 
need to be addressed regarding DKA in children 
and adolescents are whether feasible and cost-
effective methods can reduce the frequency of 
new-onset and recurrent DKA, what characterizes 
optimal fluid replacement therapy, how effective 
proposed monitoring and intervention criteria 
are in the reduction of CE morbidity and 
mortality, and whether hypertonic saline is as or 
more effective than mannitol in the treatment 
of CE.
Key points
Treatment of DKA requires first and foremost  •	
fluid resuscitation with 0.9% saline, followed 
by replacement for 5%-10% dehydration, 
depending on severity, and maintenance 
with 0.45% saline, and early and adequate 
K replacement.
Insulin should not be given as a bolus, but  •	
infused after the initial fluid resuscitation in 
a dose of 0.1 U/kg of body weight/hour.
Bicarbonate infusion is contraindicated in  •	
pediatric DKA.
CE is the most common serious complication,  •	
requiring careful neurologic and vital sign 
monitoring and early intervention with 
mannitol or hypertonic saline infusion.
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